Careology, the ground-breaking health-tech platform for cancer care, announced that they have raised £1.12M in funding from some of the UK’s leading health and technology private angel investors.
Careology is the first intelligent technology that empowers people with cancer to feel in control of their own care. It seamlessly connects them to their family and healthcare provider to enable proactive, real-time care. The data-driven platform transforms how those affected by a cancer diagnosis are supported and cared for.
Following the launch of Careology earlier this year and the incredibly exciting reaction received from healthcare providers and patients, this funding will be used to expand the Careology team, invest in sales & marketing, and accelerate its technology roadmap.
Paul Landau, CEO and Founder, comments “I am delighted to announce this funding round which will help us accelerate our launch plans, firmly establishing Careology in the market. Careology helps those affected by cancer feel supported and achieve the best possible outcome, with wide ranging benefits for healthcare providers and medical insurance companies.
Having supported my wife during her cancer journey over the last three years and experienced first-hand the daunting journey faced by patients and their family, I am hugely excited to be delivering a powerful technology platform that transforms cancer care – both during and beyond treatment. With 18m new cancer diagnosis globally each year, and climbing, Careology has been created to provide thoughtful technology that can help make things a little less complicated at a time when they’re complicated enough already.”
As part of this fundraise, Careology has also strengthened its Board, appointing serial health-tech entrepreneur, Dr. Henry Carleton as Chairman and Alan Marks, former NED of Receipt Bank as Investor Director. They join Fergus Kee, Chairman of Alina Homecare and former CEO of Bupa Insurance.
Henry Carleton said “We understand the real need for consumer-centric technology that better supports patients facing such a complex diagnosis. With Careology there is an enormous opportunity to transform the healthcare continuum and we will enable seamless connectivity and insight to clinicians responsible for patient care. Careology is well poised to become the leading global player in this nascent space.”
Alan Marks continues, “I know I speak for the Board and our investors when I say we are thrilled to be part of Careology’s goal of revolutionising cancer care. We’ve been tremendously impressed by the quality of Careology’s operations and the team, and are ready to help the company achieve its vast potential.”
Be the first to comment